Stock Traders Purchase Large Volume of Call Options on Genmab A/S (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) was the target of some unusual options trading activity on Monday. Traders acquired 12,591 call options on the stock. This is an increase of approximately 403% compared to the typical volume of 2,505 call options.

Genmab A/S Trading Up 2.2%

Shares of GMAB stock traded up $0.96 during trading hours on Monday, hitting $44.75. The company had a trading volume of 3,135,271 shares, compared to its average volume of 2,264,511. The company’s fifty day moving average is $35.25 and its 200 day moving average is $30.23. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. Genmab A/S has a fifty-two week low of $23.62 and a fifty-two week high of $45.45. The stock has a market capitalization of $27.92 billion, a PE ratio of 35.20, a price-to-earnings-growth ratio of 2.01 and a beta of 0.81.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.17. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Research analysts expect that Genmab A/S will post 1.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Signaturefd LLC lifted its stake in Genmab A/S by 8.5% during the 3rd quarter. Signaturefd LLC now owns 17,842 shares of the company’s stock worth $636,000 after acquiring an additional 1,400 shares in the last quarter. Quadrant Capital Group LLC grew its position in Genmab A/S by 3.5% in the 3rd quarter. Quadrant Capital Group LLC now owns 23,243 shares of the company’s stock valued at $850,000 after acquiring an additional 786 shares in the last quarter. Capital Square LLC acquired a new position in Genmab A/S in the 3rd quarter valued at about $219,000. Frank Rimerman Advisors LLC purchased a new stake in Genmab A/S during the third quarter worth about $244,000. Finally, Terra Nova Asset Management LLC increased its stake in Genmab A/S by 6.7% during the third quarter. Terra Nova Asset Management LLC now owns 68,527 shares of the company’s stock worth $2,445,000 after purchasing an additional 4,288 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

More Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: Genmab reported updated Phase 2 results for petosemtamab plus pembrolizumab in first-line recurrent or metastatic PD-L1-positive head and neck cancer. The combination produced a 28.2-month median overall survival, a 63% overall response rate, 9.0-month median progression-free survival and a 19% complete-response rate. Phase 3 data are expected later this year, creating a potentially important near-term catalyst. Genmab Phase 2 head and neck cancer results
• Positive Sentiment: Follow-up data for petosemtamab combined with chemotherapy in metastatic colorectal cancer showed objective response rates of 75% in first-line patients and 67% in second-line patients, including an 81% response rate among first-line patients with left-sided tumors. The results support ongoing global Phase 3 trials in colorectal cancer. Genmab colorectal cancer data
• Positive Sentiment: JPMorgan upgraded GMAB from “neutral” to “overweight,” adding Wall Street support to the positive clinical narrative. JPMorgan upgrade report
• Positive Sentiment: The Wall Street Journal reported that an experimental Genmab cancer drug reduced the risk of death and disease progression in a late-stage ovarian-cancer study, providing another favorable readout for the company’s oncology pipeline. Genmab ovarian cancer study results
• Neutral Sentiment: Although the petosemtamab results are promising, the key head and neck and colorectal programs remain dependent on confirmatory Phase 3 results, leaving clinical and regulatory risk ahead.

Analyst Ratings Changes

Several equities research analysts have issued reports on GMAB shares. Truist Financial raised their target price on Genmab A/S from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Morgan Stanley set a $42.00 target price on Genmab A/S in a research report on Tuesday, October 20th. JPMorgan Chase & Co. raised Genmab A/S from a “neutral” rating to an “overweight” rating in a research note on Monday. Weiss Ratings upgraded Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, September 1st. Finally, Guggenheim raised their price objective on Genmab A/S from $45.00 to $54.00 and gave the stock a “buy” rating in a research report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and an average target price of $43.39.

About Genmab A/S

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.